Quantifying Neuroimmune Biomarkers to Accelerate Drug Development
Tracking low-abundance proteins in blood and cerebrospinal fluid remains a primary hurdle in neuroimmunology research. On August 4, 2026, Quanterix will host a webinar detailing how ultrasensitive digital immunoassay technology allows scientists to measure subtle biological changes to better inform patient stratification and clinical trial outcomes.
The upcoming session, led by Senior Field Applications Scientist Sannette Hall, focuses on the technical shift toward detecting proteins at femtogram-per-milliliter concentrations. By capturing precise data on markers such as NfL, GFAP, sTREM2, and YKL-40, researchers can gain deeper insight into neuroaxonal injury and microglial activation. This high-fidelity measurement is designed to move beyond simple identification, enabling more reliable longitudinal monitoring and pharmacodynamic assessments in neurodegenerative and neuroinflammatory studies.
Beyond standard biomarkers, the presentation will address the technical challenges of detecting emerging targets like extracellular vesicles and low-level cytokines. The discussion aims to provide a roadmap for integrating these quantitative strategies throughout the drug development pipeline, from early discovery to clinical interpretation. Interested professionals can register for the session, scheduled for 11 a.m. EDT, to explore how these advances reduce uncertainty in therapeutic development.
Comments (0)
No comments yet. Be the first!